So Takata
Osaka University
16 Papers
So Takata is an academic researcher from Osaka University. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 6, co-authored 8 publications.
Chat about Author
Papers
Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M.
Kentaro Masuhiro,Takayuki Shiroyama,Hidekazu Suzuki,So Takata,Shingo Nasu,Hiromune Takada,Satomu Morita,Ayako Tanaka,Naoko Morishita,Norio Okamoto,Tomonori Hirashima +10 more
TL;DR: Osimertinib monotherapy is less effective in patients with NSCLC with pleural effusion, which has been unclear to date.
Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study.
Takayuki Shiroyama,Motohiro Tamiya,Seigo Minami,So Takata,Kentaro Masuhiro,Yu Futami-Nishijima,Takeshi Uenami,Masahide Mori,Taro Koba,Takanori Matsuki,Takayuki Takimoto,Hidekazu Suzuki,Norio Okamoto,Kiyoshi Komuta,Tomonori Hirashima,Atsushi Kumanogoh,Takashi Kijima +16 more
TL;DR: Carboplatin plus weekly nanoparticle albumin-bound paclitaxel is effective and well tolerated as a first-line treatment for elderly patients with advanced squamous non-small-cell lung cancer.
12
An integrative epigenomic approach identifies ELF3 as an oncogenic regulator in ASCL1‐positive neuroendocrine carcinoma
Masafumi Horie,Hidenori Tanaka,Masami Suzuki,Yoshihiko Sato,So Takata,Erina Takai,Naoya Miyashita,Akira Saito,Yoichiro Nakatani,Shinichi Yachida +9 more
TL;DR: In this paper , the authors described the epigenomic landscape of GIS-NEC and small cell lung carcinoma (SCLC) by integrating motif enrichment analysis from the assay of transposase-accessible chromatin sequencing (ATAC-seq) and enhancer profiling from a novel cleavage under targets and tagmentation (CUT&Tag) assay for H3K27ac and identified ELF3 as one of the superenhancer-related transcriptional factors in NEC.
11
Osimertinib Treatment was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
Shingo Nasu,Takayuki Shiroyama,Satomu Morita,So Takata,Hiromune Takada,Kentaro Masuhiro,Ayako Tanaka,Naoko Morishita,Hidekazu Suzuki,Norio Okamoto,Tomonori Hirashima +10 more
TL;DR: The case of a 68-year-old woman with lung adenocarcinoma with G719S, S768I, and T790M mutations in which osimertinib treatment was unsuccessful is described, suggesting that osimerinib may be ineffective for treating patients with uncommon mutations when the patient has also acquired a T790m resistance mutation.
9
Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
Takayuki Niitsu,Kiyoharu Fukushima,Sho Komukai,So Takata,Y. Abe,Takuro Nii,Tomoki Kuge,Shinichi Iwakoshi,Takayuki Shiroyama,Kotaro Miyake,K. Tujino,Satoshi Tanizaki,Kota Iwahori,Haruhiko Hirata,Keisuke Miki,Masahiro Yanagawa,N Takeuchi,Yoshito Takeda,Hiroshi Kida,Atsushi Kumanogoh +19 more
TL;DR: In this paper , the authors evaluated the efficacy of antifibrotics in patients with progressive fibrosing interstitial lung disease (PF-ILD) and compared FVC changes and overall survival (OS) between patients with and non-IPF.